MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab
January 08, 2025 07:00 ET
|
MoonLake Immunotherapeutics AG
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar...